Volume of distribution (L/kg)       :100–120 litres
half-life – normal/ESRD (hrs)      :3–4 (16 for metabolites)
DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function
10 to 20     : Dose as in normal renal function
<10           : Dose as in normal renal function
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unknown dialysability. Dose as in normal renal function
HD                     :Unknown dialysability. Dose as in normal renal function
HDF/high flux   :Unknown dialysability. Dose as in normal renal function
CAV/VVHD      :Unknown dialysability. Dose as in normal renal function
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Alcohol: may produce a disulfiram-like reactionPhenytoin: increased levels of phenytoin have been reportedWarfarin: enhanced INR
ADMINISTRATION
Reconstition
–
Route
Oral
Rate of Administration
–
Comments
–
OTHER INFORMATION
Available on a named patient basis from IDISAvoid in patients with pre-existing blood disordersHas been successfully used to treat relapsing nephrotic syndrome in children at a dose of 2.5mg/kg/alternate day. (Al-Saran K, Mirza K, Al-Ghanam G, et al. Experience with levamisole in frequently relapsing, steroid-dependent nephritic syndrome. Pediatr Nephrol. 2006 Feb; 21(2): 201–5)Has also been used in haemodialysis patients to enhance response to Hepatitis B vaccine. (Kayatas M. Levamisole treatment enhances protective antibody response to hepatitis B vaccine in hemodialysis patients.